drugset / Trial / NCT01142011

A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

NCT01142011

NaSingle-groupOpen-labelTreatment

Summary

Hypothesis; That inhibition of plasma Blys by the monoclonal antibody Belimumab will reduce both the survival of the lymphoplasmacytoid cells of Waldenstrom Macroglobulinaemia (WM), and their production of monoclonal IgM, resulting in a reduction of IgM paraprotein.

Timeline

Start
2009-11
Primary completion
2012-06
Completion
2013-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Belimumab Monoclonal antibody 10 mg/kg Intravenous